The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate [PDF]
, 2004 Gerhard W. Goerres +9 more
openalex +1 more source
KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth [PDF]
, 2017 Anastasaki, Corina +2 more
core +3 more sources
Compatibility Studies of Different Crystal Forms of Imatinib Mesylate with Pharmaceutical Excipients. [PDF]
ACS OmegaMou Y +6 more
europepmc +1 more source
Indications for Imatinib Mesylate Therapy and Clinical Management [PDF]
, 2004 François Guilhot
openalex +1 more source
Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome. [PDF]
Br J HaematolKim DH +15 more
europepmc +1 more source
Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate. [PDF]
Front Oncol, 2022 Siti Mariam I +8 more
europepmc +1 more source
Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib [PDF]
, 2004 Kk Burger, Kees Nooter
openalex +1 more source
Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. [PDF]
J Cancer Res Clin OncolZhang J +5 more
europepmc +1 more source
The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate. [PDF]
F1000Res, 2021 Wardhani SO +4 more
europepmc +1 more source